Neuron-specific enolase has potential value as a biomarker for [18F]FDG/[68Ga]Ga-PSMA-11 PET mismatch findings in advanced mCRPC patients.

Florian RosarKalle RibbatMartin RiesJohannes LinxweilerMark BartholomäStephan MausMathias SchreckenbergerSamer EzziddinFadi Khreish

Published in: EJNMMI research (2020)

We observed a significantly higher absolute serum concentration and a higher relative increase of NSE in advanced mCRPC patients with [18F]FDG-avid and insufficient PSMA expressing metastases ([18F]FDG/[68Ga]Ga-PSMA-11 mismatch findings on PET/CT) in our cohort. NSE might be used as a potential laboratory indicator for [18F]FDG/[68Ga]Ga-PSMA-11 mismatch findings, if this observation is confirmed in future, ideally prospective, studies in larger patient cohorts.

Keyphrases

pet ct
positron emission tomography
end stage renal disease
newly diagnosed
chronic kidney disease
ejection fraction
case report
risk assessment
computed tomography